Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -10,7 +10,9 @@
10	10	* It holds a leading market share in the domestic oncology segment.
11	11	* Natco has six formulation locations across India
12	12
	13	+[[image:NATCOPHARM0.png||height="241" width="614"]]
13	13
	15	+
14	14	= Company Overview =
15	15
16	16
...	...	@@ -23,20 +23,20 @@
23	23	.
24	24
25	25
26		-== Business Segments ==
	28	+== Products ==
27	27
28		-inished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). The company's focus is primarily on niche therapeutic areas and complex products. The company market and distribute its products in over 40 countries. The company sell its FDF products in the United States, India, Europe and the rest of the world (“RoW”). The company also operate in certain key geographies through its subsidiaries. {{footnote}}https://www.natcopharma.co.in/our-business/{{/footnote}}
	30	+* Glatiramer Acetate
	31	+* Liposomal Doxorubicin
	32	+* Oseltamivir
	33	+* Hepcinat and its combinations
	34	+* Sorafenat
	35	+* Geftinat
	36	+* Veenat (Imatinib)
29	29
30	30
31		-The company manufacture API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco Pharma has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.
	39	+[[image:NATCOPHARM1.png]]
32	32
33	33
34		-Natco Pharma is also engaged in contract manufacturing business, whereby the company undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. Natco Pharma has recently diversified into the business of crop health sciences to leverage its skills in organic chemistry.
35		-
36		-
37		-After carefully assessing the market potential and understanding its own strengths, Natco is targeting a unique set of molecules for the Indian market, which have a potential to expand to other regions. Natco has also entered strategic alliances with partners who will help in making inroads into the segment. The activities related to the construction of facilities in Nellore area, Andhra Pradesh has been initiated for both active ingredient and crop protection products.
38		-
39		-
40	40	== Facilities ==
41	41
42	42
...	...	@@ -48,7 +48,6 @@
48	48	* Mekaguda
49	49	* Chennai
50	50
51		-
52	52	**Formulations**
53	53
54	54	* Kothur
...	...	@@ -58,7 +58,6 @@
58	58	* Guwahati
59	59	* Visakhapatnam
60	60
61		-
62	62	**Contract Manufacturing**
63	63
64	64	* Nagarjuna Sagar
...	...	@@ -65,18 +65,33 @@
65	65	* Dehradun Unit 6
66	66	* Dehradun Unit 7
67	67
68		-
69	69	**Research & HQ**
70	70
71	71	* Research Center (NRC)
72	72	* Corporate Office
73	73
74		-
75	75	**Crop Health Sciences**
76	76
77	77	* Formulation Plant Attivaram
78	78
79	79
	78	+[[image:NATCOPHARM3.jpg]]
	79	+
	80	+
	81	+== Business Segments ==
	82	+
	83	+inished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). The company's focus is primarily on niche therapeutic areas and complex products. The company market and distribute its products in over 40 countries. The company sell its FDF products in the United States, India, Europe and the rest of the world (“RoW”). The company also operate in certain key geographies through its subsidiaries. {{footnote}}https://www.natcopharma.co.in/our-business/{{/footnote}}
	84	+
	85	+
	86	+The company manufacture API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco Pharma has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.
	87	+
	88	+
	89	+Natco Pharma is also engaged in contract manufacturing business, whereby the company undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. Natco Pharma has recently diversified into the business of crop health sciences to leverage its skills in organic chemistry.
	90	+
	91	+
	92	+After carefully assessing the market potential and understanding its own strengths, Natco is targeting a unique set of molecules for the Indian market, which have a potential to expand to other regions. Natco has also entered strategic alliances with partners who will help in making inroads into the segment. The activities related to the construction of facilities in Nellore area, Andhra Pradesh has been initiated for both active ingredient and crop protection products.
	93	+
	94	+
80	80	= Industry Overview =
81	81
82	82
...	...	@@ -188,6 +188,9 @@
188	188	NATCO has forayed into the agrichemical space through its Crop Health Sciences Division recently. Currently it is in the process to complete the manufacturing facilities for both technical (active ingredient) and formulations. NATCO is targeting the release of a key technical product from its CHS division for Chlorantraniliprole (CTPR), a broad-spectrum insecticide used in several crops, and is hoping to bring formulations based on this product with affordability and accessibility to farmers across the country. NATCO is awaiting regulatory approval for the CTPR product and litigation outcome.
189	189
190	190
	206	+[[image:NATCOPHARM2.jpg]]
	207	+
	208	+
191	191	= Financial Overview =
192	192
193	193